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Abstrak
Latar belakang: Secara alamiah protein kapsid L1 Human Papillomavirus (HPV) tipe 16 dapat mengalami 
auto assembly untuk membentuk Viral like particle (VLP). Terkait dengan penelitian vaksin HPV, VLP dapat 
digunakan untuk berbagai keperluan seperti vaksin, pseudovirion atau SpyTag-Spycatcher. Penelitian ini 
ditujukan untuk mendapatkan plasmid rekombinan yang digunakan untuk produksi protein L1 HPV 16. 
Metode: Gen penyandi protein L1 HPV 16 diklona ke dalam vector pQE80L, suatu plasmid yang mengandung 
sistem ekspresi untuk prokariota. DNA penyandi HPV 16 L1 disisipkan pada situs restriksi BamHI dan Hind III 
plasmid pQE80L. Plasmid rekombinan yang mengandung gen L1 HPV 16dikonfirmasi menggunakan PCR dan 
analisis enzim restriksi. Lebih lanjut untuk memastikan bahwa gen rekombinan L1 HPV 16 dapat diekspresikan 
dalam prokariota, plasmid rekombinan ditransformasikan ke bakteri Escherichia coli  BL21 (DE3). Bakteri 
diinduksi dengan Isopropyl β-D-1-thiogalactopyranoside (IPTG) dengan berbagai konsentrasi dan berbagai waktu 
inkubasi.                                                                                                                                            
Hasil: protein rekombinan L1, berat 56 kDa, telah berhasil diekspresikan dalam sistem prokariota. Protein 
rekombinan L1 dapat dimurnikan menggunakan TalonR dalam kondisi denaturasi.              
Kesimpulan: gen L1 HPV 16 telah dikloning ke dalam pQE80L dan berhasil diekspresikan dalam sistem 
prokariota. (Health Science Journal of Indonesia 2019;10(2):82-9)
Kata kunci: L1, HPV 16, cervical cancer
Abstract
Background: Naturally Human Papillomavirus (HPV) type 16 L1 capsid protein can auto assemble to 
form Viral like particles (VLP).  Concerning to vaccine development for HPV, VLP can be used for a 
variety of needs such as a vaccine, pseudovirion or SpyTag-Spycatcher.  In this study, to obtain a vector 
expression that can be used in the production of HPV L1 protein, we cloned gene coding HPV 16 L1 
protein into pQE80L a plasmid contains an expression system for prokaryote. 
Methods: The DNA coding HPV 16 L1 was inserted at BamHI and Hind III restriction sites of pQE80L 
plasmid. The recombinant plasmid containing the HPV L1 gene was confirmed using PCR colony and 
enzyme restriction. Further to ensure the recombinant HPV 16 L1 gene could be expressed in a prokaryote, 
the recombinant plasmid was transformed into bacteria Escherichia coli BL21 (DE3). The bacteria were 
induced with IPTG with various concentrations and various incubation time. 
Result: L1 recombinant protein, 56 kDa in weight, has successfully been expressed in prokaryote system.  
L1 recombinant protein can be purified using TalonR under denaturing conditions. 
Conclusion: L1 HPV 16 gene has been cloned into pQE80L and successfully expressed in prokaryote 
system. (Health Science Journal of Indonesia 2019;10(2):82-9)
Keywords: L1, HPV 16, cervical cancer 
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Human papillomavirus (HPV) is the major caused 
of cervical cancer that causes death of 311000 
women in 2018. 1 Based on their capability in 
inducing cancer, the HPV viruses are divided into 
2 groups, the high risk and the low-risk group.2 
Consisted of at least 9 HPV subtypes, those are HPV 
6,11,16,18,31,32, 45,52, and 58, the high-risk group 
is associated with 90% of cervical cancer and 90% 
of genital warts.3 Approximately 67% of cervical 
cancer globally was caused by HPV16 and 18.4  The 
main strategy to prevent HPV infection recommended 
by WHO is by vaccination. Nowadays there are three 
kinds of commercial prophylactic HPV vaccines, 
that are Gardsil, a quadrivalent vaccine containing 
HPV 6,11,16,18 antigens, Gardasil 9, a 9-valent 
vaccine containing HPV 6,11,16,18,31,33,45,52,58 
antigens and a bivalent vaccine against HPV16 and 18 
antigens.3 The WHO recommends that the commercial 
HPV vaccine must cover at least two kinds of HPV 
subtypes, HPV 16 and HPV18 antigens.5      
HPV is an unenveloped virus that has a circular 
double-stranded DNA genome of approximately 8 
kb in size. 6 HPV has a capsid that formed by HPV 
major and minor capsid protein, which are Late 
(L) 1 and L2 proteins respectively.  Naturally, L1 
without the presence of other HPV structural and 
non-structural proteins has the capability to self-
assemble to form virus-like particles (VLP).7 Capsid 
proteins contain conformational epitopes that induce 
neutralizing antibodies. 8 Capsid proteins contain 
positively charged amino acids causing DNA that has 
negative charge can be assembled into VLP.9 Based 
on its natural unique properties, many studies have 
explored the potentiality of L1 protein to be developed 
as vaccine, pseudovirion, and vehicle to deliver 
immunomodulator, adjuvant, DNA and proteins. 7,8,9  
Infection of HPV will be followed by serologic 
immune responses that mainly directed against 
conformational epitopes of viral capsid proteins, 
and this response will persist for many years.9 
Immunization of VLP will induce immune responses 
that resembling HPV infection because VLP presenting 
neutralizing antibody epitopes that are similar to those 
presented on the virus.8 Thus, unlike a virus, VLP 
does not contain viral genome so the expression of 
proteins inducing cancers such as E6 or E7 can be 
avoided. Nowadays, in vaccine industries, there are 2 
technologies used to produce L1 HPV vaccine,  which 
is a yeast-expression (Saccharomyces cerevisiae) and 
Baculovirus-expression system. 8 By using these 
techniques, the mass of production of HPV vaccine 
becomes possible.  The other promising expression 
system that could be developed as a production host 
of L1 protein is prokaryote. 11, 3  
Due to the limitation in providing a susceptible cell 
culture that can be infected by HPV, the capability of 
the antibody to prevent HPV infection was measured 
by using pseudovirion. Pseudovirion is L1 VLP that 
assemble DNA coding a certain reporter protein, such 
as green fluorescent protein (GFP). The production of 
pseudovirion is conducted by co transfecting plasmid 
coding L1 and L2 and plasmid coding reporter genes 
in 293 TT cell culture.  L1 and L2 protein will be 
produced and assembled into VLP, and during the 
formation of VLP the DNA coding reporter gene will 
incorporate to VLP.  The corporation of DNA to VLP 
is through the interaction of negative charge of the 
DNA with positive charges of the L1 amino acid. 
Like in HPV infection, pseudovirion enters cells via 
the interaction of VLP with HPV receptor expressed 
on 29TT cell, Heparan sulfate.12  In neutralization 
assay, in the absence of neutralizing antibody, 
pseudovirion can enter cell culture, 293TT, and 
the reporter protein will be expressed. On the other 
hand, in the presence of neutralizing antibodies, the 
pseudovirion will be neutralized and cannot enter the 
cell causing reporter protein will not be expressed. 
Beside beneficial in medicine, VLP also useful in 
nanotechnology.13 SpyTag-Spy catcher technology 
or protein In nanotechnology, VLP can be decorated 
with a different antigen or protein. Decorating VLPs 
with target-antigens by genetic fusion of chemical 
modification is time-consuming and often leads to L1 
protein miss folding or miss assembly. Some studies 
have been conducted to establish a platform for 
irreversibly decorating VLP simply by mixing with 
a protein of interest. One of the technologies used to 
develop irreversible decoration of VLP is Sphycatcher 
and SpyTag. Sphycatcher is a genetically-encoded 
protein designed to spontaneously form a covalent bond 
to its peptide partner.13 Generally, a protein that has the 
capability to form a highly organized supramolecular 
structure with unique biological properties is chosen 
to be a Spy catcher.14 The protein of interest tagged 
with peptide SpyTag form an irreversible covalent 
bond to the spy catcher protein via a spontaneous 
isopeptide linkage to create a peptide interaction that 
resists force and harsh conditions.15 Even though the 
usage of L1 HPV as Spycartcher has been reported 
yet, L1 HPV is potential to be developed as Spy 
catcher. L1 could assembly to form big, stable 
molecules. A peptide that mediates spy catcher and 
spy tag interaction can be inserted in one of 5 major 
loops of L1 protein.   
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In this study, we construct the plasmid containing 
gene coding L1 HPV subtype 16. Plasmid will be 
used in the production of HPV 16 L1 protein. The 
HPV 16 L1 protein will be used in many studies, 
such as in the development of spy taq-spy cather 
nanotechnology or producing specific antibodies that 
can be used for diagnostic or other serological assays 
for HPV 16. More over producing HPV 16 L1 will 
give valuable experiences for developing vaccine or 
pseudovirion for other high risk HPV.  Technically, 
producing recombinant protein in a prokaryote is 
simpler than in yeast or Baculovirus. The production 
of recombinant protein in bacteria does not need the 
expensive facility. 1,23,24,25,26   
METHODS 
L1 coding gene. L1 used in this study a sequence 
is obtained from a back translation of the consensus 
sequence of L1 protein using DNA2 and has been 
codon optimized in accordance with prokaryote 
expression system. The L1 consensus sequence 
was generated by picking up the most frequent 
amino acid present at each position in a L1 protein 
alignment. The sequence of L1 full length proteins 
were collected from Genbank with accession 
number :  AD33259.1, AIQ82831.1, ACN91168.1, 
AIQ82846.1, AIQ82845.1, AIQ82844.1, 
AIQ82843.1, AIQ82842.1, AIQ82841.1, 
AIQ82840.1, AIQ82839.1, AIQ82838.1, 
AIQ82837.1, AIQ82836.1, AIQ82835.1, 
AIQ82834.1, AIQ82833.1, AIQ82832.1, 
AIQ82829.1, AIQ82830.1. The L1 gene containing 
an open reading frame (ORF) of L1 protein with 
length 1515 bp was synthesized in IDT Malaysia via 
local supplier. The gene was cloned into universal 
cloning vecor pUC 19, and plasmid containing L1 
gene was name pUCL1col. The sequence of L1 
gene and protein is confidential because a patent is 
currently being filed. 
Subcloned gen coding   HPV 16 L1 protein into 
pQE80L.  Gene coding HPV 16 L1 was subcloned 
from pUCL1col (obtained from PRVKP FKUI 
RSCM) to pQE80L (Qiagen) inserted in BamHI 
and HindIII fragment. Vector and insert used in 
the subcloned reaction were prepared by restricted 
10 µg plasmid of each pQE80L and pUCL1col. 
The restriction was performed by adding 10 µg in 
a tube containing 1x Neb2 buffer, 1xBSA (NEB) 
and 40.000 Unit BamHI (NEB) and DNAseRNAse 
free water (Ambion) to volume 100µl. The mixture 
was incubated for 4 hours at 37oC. After that, the 
DNA was desalted using QiaecII gel extraction kit 
(Qiagen) following the procedure described by the 
manufacturer. Further, DNA was restricted by HindIII. 
DNA that has been cut with BamHI was added to a 
tube containing 1x Neb4 buffer, 1xBSA, and 40.000 
Unit HindIII (NEB) and DNAseRNAse free water 
(Ambion) to volume 100µl. After incubated overnight 
at 37oC, DNA was run on 0.8% LMA containing 
crystal violet (Invitrogen). DNA was purified from 
LMA by using S.N.A.P UV-free DNA isolation kit 
(Invitrogen). Ligation was performed by using vector: 
insert comparison = 1:3. Ligation reaction is 80 ng 
vector, 80 ng insert, 1x ligation buffer (NEB), 2.5 
Unit T4 Ligase (NEB) and water to volume 20 µl. 
reaction ligation was incubated at 16oC for overnight. 
Ligation was transformed into chemically competent 
Escherichia coli Top1016 by the heat shock method.  
Modeling Ribo Nucleic acid (RNA) secondary 
structure 
The secondary structure of messenger RNA is 
generated from the HPV 16 L1 sequence (the 
sequence is unpublished) using the dynamic 
programming algorithm described in  MaxExpect 
program.17 The software can be accessed freely 
at Mathews Lab Home – University of Rochester 
(https://rna.urmc.rochester.edu)   
Selection of recombinant cloned
Recombinant bacteria containing recombinant plasmid 
coding HPV 16 L1 was screened using PCR colonies. 
Primers pQEF (GTATCACGAGGCCCTTTCGTCT) 
and pQER (CATTACTGGATCTATCAACAGGAG) 
that recognizing specific sites in pQE80L was used 
to amplify the DNA inserted in multiple cloning sites. 
The PCR reaction was performed using DreamTaq 
DNA polymerase (Thermoscientifict) following the 
manufacturer’s instruction (Thermoscientifict). Bacterial 
colonies were picked up using sterile toothpick strikes on 
replica plates and put into PCR tubes as PCR template. 
The colonies producing expected DNA amplicons 
were grown in 4 ml LB broth containing 100 µg/ml 
ampicillin, incubated at 37oC overnight.  Plasmids were 
isolated using Miniprep (Qiagen) and characterized 
using enzyme restriction.16 Further plasmid was sent 
to IDT Malaysia via local supplier for sequencing by 
using Sanger Method to verify the gene sequence. The 
shipment of DNA was accompanied by Material transfer 
agreement (MTA) signed by sender and receiver. MTA 
stated that the receiver was allowed to use the DNA only 
for method stated in research protocol.  
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Protein expression
The verified plasmid was transformed into 
bacteria Escherichia coli BL21 (DE3) chemically 
competence using heat shock transformation.23 
Three colonies were picked up and cultured in 4 ml 
LB broth containing 100 µg/ml ampicillin, incubated 
overnight at 37oC. One part of overnight culture 
was grown in 20 part of Terrific broth (Gliserol 1%, 
Trypton 1,2%, Yeast extract 1,2%, KH2PO4 0,34%, 
K2HPO4 (1,1%) containing 100 µg/ml ampicillin, 
after incubated for  1.5 hours, the cultures were 
incubated on ice for 15 minutes, and IPTG with 
various final concentration (0,1; 0,2 dan 1 mM ) 
was added, and 1 ml cultures were collected  after 
3, 6 and overnight after induction. The incubation 
temperature of induction was 37oC. 
Protein purification  
Bacteria were lysed under native and denature 
conditions. In native condition, bacteria were lysed 
using buffer A (500mM Tris-HCl (pH 8.0), 1 mM 
EDTA, 1 mM DTT, 100 mM NaCl, 20%Sucrose, 
1mg/ml Lyzosime. Under denature condition, 
bacteria were lysed using denature buffer (50mM 
Sodium Phosphate, 6 M Guanidine HCl, 300mM 
NaCl (pH8)). After incubated for 1 hour 20 
minutes on rocking incubator 60 rpm (BioRad) at 
room temperature. After incubates, samples were 
centrifuged at 12000 rpm for 5 minutes at 4oC. 
Protein was purified using TALON® (Clontech) 
and the purification was conducted following the 
manufacturing instruction. Wash buffer used here 
was 45 mM Sodium Fosfat, 300mM NaCl, 5,4 M 
Urea, 10 mM imidazole (pH 8,0). Recombinant 
protein was eluted using 45 mM Sodium Fosfat,   dan 
300mM NaCl, 5,4 M Urea, 150/200 mM imidazole 
(pH 8,0).  The purified recombinant protein was 
analyzed by run it on 12% SDS PAGE.  
RESULTS 
Linearized vector and L1 gene insert were 
successfully isolated from LMA, 4800 and 1515 bp 
respectively (Figure 1). After ligated recombinant 
plasmids were transformed into E.coli Top10, the 
growing colonies were subjected to PCR colony. The 
colonies produced 1840 bp amplicon indicated those 
colonies possibly contain the interested DNA. The 
pQE80L Wild type (WT) produced 289 bp DNA that 
closely migrated to 300 bp marker (Figure 2). 
Figure 1. Schema of Subcloning plan (A) and vector (line 1) and insert (line 2)  (B) 
Figure 2.  Screening of Recombinant plasmid. (A) PCR colony. M : Marker, K1 pQE80L WT, K2: 
Negative control, 1 pQE80L L1. (B) Restriction enzyme analysis pQE80L L1 with BamHI 
and HindIII, the arrow showed the fragment of L1 gene. (C). Sequencing result showed the 
position of L1 gene that was in frame with 6xHis.
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Plasmids were isolated from PCR confirmed colonies. 
Once run on 0.8% agarose gel, recombinant plasmids 
migrated slower than pQE80L WT, indicating the 
size of those plasmids due to the insertion of L1 gene 
became larger than pQE80L WT (data was not shown). 
The recombinant plasmids were further analyzed using 
restriction enzyme. The recombinant plasmids produced 
DNA fragments 4800 and 1515 bp in length (Figure 2). 
The sequencing showed the inserted-gene sequences 
were not mutated and can be expressed in frame with 
6xHis Tag (the full sequence of L1 was not shown).  
The verified recombinant plasmid was transformed 
in bacteria hopes that used for recombinant protein 
production, BL21 (DE3). After inducing with IPTG 
with various concentrations showed there was 
overexpression of protein that migrates between marker 
55 and 70 kDa, indicating L1 recombinant proteins were 
successfully expressed. Based on SDS page analysis, 
the 0.1 mM IPTG could induce the recombinant L1 as 
efficient as other IPTG concentrations. The recombinant 
bacteria could be expressed 3 hours after the addition 
of IPTG. Prolonged induction time to overnight also 
induced unspecific host protein (Figure 4). Analysis of 
messenger RNA secondary structure showed the RBS 
(AGGAG) in a single-stranded structure, and the last 
base (G24) of start codon formed external closing pair 
with T91, however that interaction did not infer protein 
expression. 
Figure 3. (A) The secondary structure modeling of  5’UTR  L1-mRNA 
covering the ribosomal binding site and start codon generated by 
Maxexpect program. (B) The expression of L1 recombinant protein 
in E.coli  BL21 (DE3) induced with various concentrations of 
IPTG and length of induction time. M: marker, 1-3 bacteria were 
induced for 3 hours at various concentrations of IPTG, no 4-6 
were induced for 6 hours at various concentrations of IPTG, no 
7-9 were induced for overnight at various concentrations of IPTG. 
The concentrations of IPTG: 0.1, 0.25 and 1 mM respectively. No 
10: wild type BL21 (DE3). UTR: untranslated region.
Figure 4. (A)  Lysed bacteria M: Marker, 1: Supernatant 2: pellet 3: 
BL21 (DE3) expressing L1. (B)  Purification of L1 recombi-
nant using Talon, M: Marker, 1 BL21 (DE3) expressing L1, 
2-6: the elution of L1 recombinant, 7-8: washed.
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After lysed using native buffer, the recombinant 
L1 predominantly found in the pellet (Figure 4), 
indicating the protein retains in inclusion bodies. 
L1 recombinant protein fused with 6xHistidine Tag 
was successfully purified under denaturing condition 
using TalonR. However, the protein also could be 
found in washing filtrate. Protein started to elute 
when incubated with elution buffer containing 150 
mM Imidazole (Figure 4).     
DISCUSSIONS
Bacteria containing plasmid coding gene of interest 
can be selected by combining some methods, such 
as PCR colonies, restriction profile of enzyme 
restriction of plasmid, a specific selectable marker, 
and sequencing.  In this study, we used PCR colony 
as the 1st method to screen the bacteria bearing 
interested recombinant plasmid. In this study primer 
pair, pQEF and pQER, that recognized a specific 
region that flanks open reading frame of pQE80L 
was used in PCR colony. The amplification using 
pQEF and pQER causes the addition of 289 bp to 
the insert length (figure 2A) and the amplification 
of 289 pb in wild type palsmid (figure 2A). Specific 
primers that recognize gene of interest also can be 
used, but the possibility of the altering of primer 
annealing temperature after that gene was cloned 
into a vector must be taken into consideration. 
The second method to screen plasmid is based 
on the migration of plasmid on an agarose gel. 
The insertion of a gene into a plasmid causes the 
addition of plasmid size. Once run on agarose gel the 
recombinant plasmid will run slower than wild type. 
Further, the recombinant plasmid can be confirmed 
by DNA restriction pattern.  Enzyme restriction has 
a specific target on DNA either plasmid or insert. 
In this study, the recombinant plasmid was cut with 
BamHI and HindIII. Those enzymes locate at 5’ and 
3’ terminal of pQE80L cloning sites. The restriction 
of recombinant plasmid using BamHI and HindIII 
causes the separation of vector, 4800 bp, and insert 
1515 bp (figure 2B). The sequence of interesting 
genes was confirmed using sequencing. By using 
proper software, the amino acid sequence of the 
inserted gene can be analyzed whether it in frame 
with 6xHistidine Tag or not. In this study, the L1 
HPV 16 gen was cloned in frame with 6x His (figure 
2C). L1 HPV16 recombinant can be expressed in 
prokaryote system that showed by the overexpression 
of 56 kDa protein band after induction with IPTG, 
whereas that band could not be found in wild type. 
The L1 gene used here was codon optimized in 
accordance to prokaryote to minimize the hindering 
of protein translation due to codon bias [11]. Based 
on mRNA modelling, the ribosomal binding site 
was in a single-stranded or un structure. Modelling 
was used to predict the translation probability of a 
mRNA in host cells.18,19 Protein production in E.coli 
depends on the capability of 16sRNA to bind to a 
specific segment of mRNA called Shine Dalgano 
or ribosomal binding site [20]  and the interaction 
only occurs when the SD/RBS in a single-stranded 
or unstructured state.21 The interaction of SD/RBS 
with 16sRNA will be followed by the interaction 
of ribosome-bound initiator tMet with start codon 
(ATG). Based on RNA modelling, the last base of 
HPV 16 L1 ATG interacted with T91. However, 
this interaction does not hinder protein translation. 
Predicted RNA structure that generated based on the 
full sequence of mRNA probable difference to those 
generated in living system.22 During transcription and 
translation process in vivo the elongation of mRNA 
chain occurs simultaneously with protein synthesis. 
Ribosome complex has occupied SD and ATG before 
the mRNA elongation reaches certain base that 
pairing with ATG.18  By using Talon (Clontech), 
the recombinant HPV 16 L1 could be purified 
under denature condition, because under native 
condition, the protein retained in pellet.  Previously 
been reported, L1 protein expressed in E.coli 
retained in inclusion bodies.23,24 High level protein 
expression, high temperature during expression, 
high concentration of IPTG, the usage of strong 
promoter, partially folded or misfolded protein often 
results in aggregation of the recombinant protein 
into inclusion bodies.25 By using chaotropic agents 
such as Guanidine HCl and Urea, the recombinant 
protein in inclusion bodies can be solubilized.26 On 
the other hand, the presence of chaotropic agents can 
denature the protein.  The denatured recombinant 
protein can renature by dialysis or diluting in native 
buffer. 26, 27 Therefore, modification of L1 protein at 
N-terminal has been reported could solubilize L1, 
and such modification did not affect the capability of 
L1 to self-assembly.3 
The L1 protein of HPV 16 can be produced in 
various expression system, and the currently HPV 
prophylaxis vaccines were produced in mammalian 
system, that are Baculovirus and Yeast.11,24,28,29,30,31,32 
Compared to those mammalian expression systems, 
E.coli has some advantages such as fast growth, 
easy gene manipulation, low production cost and 
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easy to scale up.28 Thus this system is suitable for 
low-income countries where cervical cancer results 
in higher mortality, and this expression system has 
been used to produce a low-cost HPV vaccine by 
Xiamen Innovax Biotech, China (Huang et al, 2017). 
The sources of L1 gene used to developed VLP 
are varying. The gene could be amplified from 
keratynocyte cell line W12 (28), synthesized based 
on L1 gene downloaded from Genbank11, extracted 
from patients30, or ordered from ATTC company.33 
L1 gene used in this research is synthetic gene that 
codes a consensus L1 protein that represents the 
majority amino acid presented in different L1 HPV 
16 proteins. Consensus sequence can accommodate 
the diversity of L1 HPV 16.34 Vaccine based on 
consensus sequence expectantly could induce strong 
and broad immune response.34 
In conclusion, gene coding HPV 16 L1 has been 
successfully cloned into pQE 80L, a prokaryote 
expression system. The cloned gene can be expressed 
E.coli in BL21(DE3) and can be purified using TalonR.
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